Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton

Clinical and Experimental Metastasis

Volumn 15, Issue 3, 1997, Pages 205-217

  Reyes Moreno, Carlos ^a   Koutsilieris, Michael ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

insulin like growth factor I; osteoblastic metastasis; prostate cancer; transforming growth factor 1; urokinase type plasminogen activator

Indexed keywords

CHLORAMPHENICOL ACETYLTRANSFERASE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; THYMIDINE KINASE; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ANIMAL CELL; ARTICLE; CELL INTERACTION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; GROWTH INHIBITION; METASTASIS; MITOGENESIS; NONHUMAN; OSTEOBLAST; PROSTATE CANCER; RAT; RECEPTOR DOWN REGULATION; REPORTER GENE;

ANIMALS; BONE NEOPLASMS; CELL COMMUNICATION; CELL DIVISION; DEXAMETHASONE; DNA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; OSTEOSARCOMA; PROSTATIC NEOPLASMS; RATS; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030909399     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018413229570     Document Type: Article

References (46)

1. Davies P and Rushmere NK, 1992, Association of glucocorticoid receptors with prostate nuclear sites for androgen receptors and with androgen response elements. J Mol Endocr, 5, 117-27.
2. Koutsilieris M, Grondin F and Lehoux J-G, 1992. The expression of mRNA for glucocorticoid receptor gene and functional glucocorticoid receptors detected in PA-III rat prostate adenocarcinoma cells. Anticancer Res, 12, 899-904.
3. Reyes-Moreno C, Frenette G, Lavergne E, Boulanger J, Govindan MV and Koulsilieris M, 1995, Mediation of glucocorticoid receptor function by transforming growth factor beta 1 (TGFβ1) expression in human PC-3 prostate cancer cells. Prostate, 26, 260-69.
4. Evans RM, 1988, The steroid and thyroid hormone receptor superfamily. Science, 240, 889-95.
5. Jonat C, Rahmsdorf HJ, Park KK et al. 1990, Antitumor promotion and antiinflamation: down-modulation of AP-1 (fos/jun) activity by glucocorticoid hormone. Cell, 60, 1189-204.
6. 1 block in cell cycle progression. Cell Growth Different, 4, 215-25.
7. Johnson BH, Gomi M, Jacowlew SB, Moriwaki K and Thompson EB, 1993, Actions and interactions of glucocorticoids and transforming growth factor β on two related human myeloma cell lines. Cell Growth Differ, 4, 25-30.
8. Syms AJ, Norris J and Smith RG, 1984, Autocrine regulation of growth: I. Glucocorticoid inhibition is overcome by exogenous platelet derived growth factor. Biochem Biophys Res Commun, 122, 68-74.
9. Pollard M, Luckert PH and Scheu J, 1988, Effects of diphosphonate and X-rays on bone lesions induced in rats by prostate cancer cells. Cancer, 61, 2027-32.
10. Hoover DM, Best KL, McKenney BK, Tamura RN and Neubauer BL, 1990, Experimental induction of neoplasia in accessory sex organs of male Lobund - Wistar rats. Cancer Res, 50, 142-6.
11. Koutsilieris M, 1992, PA-III rat prostate adenocarcinoma cells. In Vivo, 6, 199-204.
12. Galasko CSB, 1982, Mechanism of lytic and blastic metastatic disease of bone. Clin Orth Rel Res, 12, 20-5.
13. Koutsilieris M, Rabbani SA and Goltzman D, 1986, Selective mitogens can be extracted from prostatic tissues. Prostate, 9, 109-115.
14. Koutsilieris M, Rabbani SA and Goltzman D, 1987, Effects of prostatic mitogens on rat bone cells and fibroblasts. J Endocrinol, 115, 447-54.
15. Koutsilieris M, Rabbani SA, Bennett HPJ and Goltzman D, 1987, Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest, 80, 941-6.
16. Rabbani SA, Desjardins J, Bell AW et al. 1990, An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun, 173, 1058-62.
17. Koutsilieris M, Frenetic G, Lazure C, Lehoux J-G, Govindan MV and Polychronakos C, 1993, Urokinase-type plasminogen activator: a paracrine factor regulating the IGFs bioavailability in PA-III cell-induced osteoblastic metastases. Anticancer Res, 13, 481-6.
18. Koutsilieris M and Polychronakos C, 1992, Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. Anticancer Res, 12, 905-10.
19. Campbell PG, Novak JF, Yanosick TB and McMaster JH, 1992, Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology, 130, 1401-12.
20. Yee JA, Yan L, Dominguez JC, Allan EH and Martin TJ, 1993, Plasminogen-dependent activation of latent transforming growth factor beta (TGFβ) by growing cultures of osteoblast-like cells. J Cell Physiol, 157, 528-34.
21. Bernard JA, Lyons RM, and Moses HL, 1990, The cell biology of transforming growth factor beta. Biochim Biophys Acta, 1032, 79-87.
22. Koutsilieris M, 1993, Osteoblastic metastasis in advanced prostate cancer. Anticancer Res, 13, 443-50.
23. Koutsilieris M, 1995, Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Hema/Oncol, 18, 51-64.
24. Polychronakos C, Janthly U, Lehoux J-G and Koutsilieris M, 1991, Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. Prostate, 19, 313-21.
25. 4. Nature, 227, 680-5.
26. Govindan MV, 1990, Specific region in hormone binding domain is essential for hormone binding and trans-activation by human androgen receptor. Mol Endocr, 4, 417-27.
27. Chen TL, Cone CM and Feldman D, 1983, Glucocorticoid modulation of cell proliferation in cultured osteoblast-like bone cells: differences between rat and mouse. Endocrinology, 112, 1739-45.
28. Peck W, Gennari C and Raisz L, 1984, Corticosteroids and bone. Calcif Tissue Int, 36, 4-7.
29. Colvard DS, Eriksen EF, Keeting PE et al. 1989, Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA, 86, 854-9.
30. Oursler MJ, Riggs L and Spelsberg TC, 1993, Glucocorticoid-induced activation of latent transforming growth factor-β by normal human osteoblast-like cells. Endocrinology, 133, 2187-96.
31. Boulanger J, Reyes-Moreno C and Koutsilieris M, 1995, Mediation of the glucocorticoid receptor (GR) function by the activation of latent transforming growth factor beta 1 in MG-63 osteoblast-like osteosarcoma cells, Int J Cancer, 61, 692-7.
32. Delany AM and Canalis E, 1995, Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells. Endocrinology, 136, 4776-81.
33. Koutsilieris M, Faure N, Laroche B, Tolis G, Roberts G and Ackman CFD, 1986, Objective response and disease outcome in 59 patients with stage D2 prostatic carcinoma treated with either buserelin or orchiectomy: disease aggressivity and its association with response and outcome. Urology, 27, 221-7.
34. Koutsilieris M, Laroche B, Thabet M and Fradet Y, 1990, The assessment of disease aggressivity in stage D2 prostate cancer patients. Anticancer Res, 10, 333-6.
35. Koutsilieris M, Dupont A, Gomez J et al. 1994, Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormone therapy (GnRH-A plus flutamide). Anticancer Res, 14, 627-34.
36. Tubiana-Hulin M, 1990, Traitement hormonal des metastases osseuses des cancers. Rev Rheum, 57, 821-7.
37. Hellmann K, Philips RH and Goold M, 1993, High dose dexamethasone and base of brain irradiation for hormone refractory metastatic carcinoma of the prostate. Clin Exp Metastasis, 11, 227-9.
38. Steiner MS and Barrack E, 1992, Transforming growth factor-β1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocr. 6, 15-25.
39. Wilding G, Zugmeier G, Knabbe C, Flanders K and Gelmann E, 1989, Differential effects of transforming growth factor ßon human prostate cancer cells in vitro. Mol Cell Endocr, 62, 79-87.
40. Chiquet-Ehrismann R, Kalla P, Pearson CA, Beck K and Chiquet M, 1988, Tenascin interferes with fibronectin action. Cell, 53, 383-90.
41. Heino J, and Massaque J 1989, Transforming growth factor-β switches the pattern of integrins expressed in MG-63 human osteosarcoma cells and causes a selective loss of cell adhesion to laminin. J Biol Chem, 264, 21806-11.
42. Yang EY and Moses HL, 1990, Transforming growth factor β1-induced changes on cell migration, proliferation and angiogenesis in chicken chorioallantoid membrane. J Cell Biol, 111, 731-41.
43. Gehron-Robey P, Young MF, Flanders KC et al. 1987, Osteoblasts synthesize and respond to transforming growth factor-type β (TGF-β) in vitro. J Cell Biol, 105, 457-2.
44. Centrella M, Horowitz MC, Wozney JM and McCarthy TL, 1994, Transforming growth factor-β gene family members and bone. Endocr Rev. 15, 27-39.
45. Ibbotson KJ, Orcutt CM, Anglin AM and D'Souza SM, 1989, Effects of transforming growth factor β1 and β2 on a mouse clonal osteoblast-like cell line MC3T3-E1. J Bone Miner Res, 1, 37-44.
46. Koutsilieris M, Dimopoulos MA, Doillou C, Sourla A, Moreno-Reyes C and Choki I, 1996, The molecular concept of prostrate cancer. Cancer J, 9, 89-94.